Most drug makers' revenue growth fails to propel profit as much
Leading drug makers showed a double-digit revenue growth year-on-year in the nine months through March this year, but the rise in their profits was much slower in comparison during the period for escalation in business cost. Increased raw material prices, energy costs and interest expenses p